Background/Aims Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA).
Methods A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Hazard ratios (HRs) were pooled using a random-effects NMA and validated in an in-house cohort of 1,008 LT recipients.
Results Among 22,466 articles identified, 35 studies with 45 pairwise comparisons were included in the NMA along with 8 different EC. The University of California San Francisco (HR, 1.43; 95% CI, 1.19–1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15–1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11–2.57) showed inferior OS to the MC. The MC ranked highest for both OS and RFS, followed by Metroticket 2.0 for OS and the Asan criteria for RFS. In the validation cohort, both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC.
Conclusions Several EC, of which those of Metroticket 2.0 were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.
Citations
Citations to this article as recorded by
Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Giusy Senese, Annachiara Coppola, Patrizia Iodice, Simone Olivieri, Alessandro Federico, Marcello Dallio Journal of Clinical Medicine.2026; 15(10): 3579. CrossRef
Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation Juraj Prejac, Domina Kekez, Hana Lučev, Borna Ćutić, Viktor Domislović, Vibor Šeša, Gordan Adžić, Marin Golčić Journal of Clinical Medicine.2026; 15(10): 3923. CrossRef
Improving the choice of liver transplant for hepatocellular carcinoma: Editorial on “Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein” Jongman Kim Clinical and Molecular Hepatology.2026; 32(3): 1461. CrossRef
From post-transplant outcomes to listing decisions: Clinical implications of comparing expanded hepatocellular carcinoma transplant criteria: Letter to the editor on “Network meta-analysis and validation study of expanded liver transplantation criteria fo Bo Ni, Hairui Wang Clinical and Molecular Hepatology.2026; 32(3): e315. CrossRef
Risk Stratification of Hepatocellular Carcinoma Recurrence After Liver Transplantation: A 25-Year Single-Center Study Comparing Pre- and Post-Transplant Prognostic Models Andrea González De Godos, Martín Bailón Cuadrado, Paloma Lourdes Rodríguez Vielba, Pilar Pinto Fuentes, David Pacheco Sánchez Journal of Clinical and Experimental Hepatology.2026; : 103677. CrossRef
Young Eun Chon, Ju Hyun Shim, Joo Hyun Oh, Jiwon Yang, Hyunjae Shin, Wonseok Kang, Yeongseok Hwang, Su Jong Yu, Jongman Kim, Hae Won Lee, Yoon Jun Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2025;31(4):1107-1114. Published online October 1, 2025
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee Cancer Immunology, Immunotherapy.2026;[Epub] CrossRef
First
Prev
